Source: School Course 13



Rating:

Share or cite this content

Citations should be made in the following way:
I. Abubakar (London, UK). Trials for TB infection and disease drugs: special aspects. School Course 13

Member's Comments

No comment yet.

Related content which might interest you: Trials for TB infection diagnostics: designing a protocol Source: School Course 13 Year: 2013 Trials for TB disease diagnostics: designing a protocol Source: School Course 13 Year: 2013 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Anti-tuberculosis drug concentrations and treatment outcomes in patients with both tuberculosis and HIV infection Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013 Latent tuberculosis infection prevalence and risk of developing active TB among patients eligible for starting anti-TNFα therapy Source: International Congress 2015 – Screening strategies in TB Year: 2015 The effectiveness of TB treatment in patients with gastrointestinal tract disorders, depending on the way of administration of anti-TB drugs Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 Screening and monitoring of TB infection in rheumatological patients on biologics therapy Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Should patients with active tuberculosis be routinely screened for chronic viral hepatitis? Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014 The change of tuberculosis features through decades in immune-competent patients Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Clinical and epidemiological data in Tuberculosis (TB) - AIDS patients Source: Eur Respir J 2005; 26: Suppl. 49, 426s Year: 2005 Annual prevalence and treatment estimates of nontuberculous mycobacterial pulmonary disease in Europe: A NTM-NET collaborative study Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015 Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Are epidemiological statistics on extrapulmonary tuberculosis correct? Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease Year: 2016 Control of MDR-/XDR-TB and elimination of TB in Europe: status update Source: Annual Congress 2012 - Fighting MDR- and XDR-TB in Europe: from programme results to research implementation Year: 2012 The Tuberculosis Network European Trials Group (TBNET): new directions in the management of tuberculosis Source: Breathe, 13 (3) e65; 10.1183/20734735.005517 Year: 2017